Table 4.

Adverse events according to treatment group

Calcitriol, n=64Cholecalciferol, n=64
Serious adverse events
 No. of hospitalizations, N (%)13 (20)13 (20)
 Reasons for hospitalizations
  Infections2 (15)1 (8)
  Congestive heart failure exacerbation2 (15)1 (8)
  Volume overload not caused by congestive heart failure0 (0)3 (23)
  Myocardial infarction/stroke0 (0)2 (15)
  Angina1 (8)1 (8)
  Shortness of breath2 (15)2 (15)
  Pneumonia0 (0)1 (8)
  Surgery5 (38)2 (15)
  Pancreatitis1 (8)0 (0)
 No. of deaths, N (%)0 (0)2 (3)
  Deaths related to the study00
Expected adverse events
 Hypercalcemia (calcium >10.5 mg/dl), N (%)4 (6)1 (2)
 Hyperphosphatemia, N (%)
  Phosphate >4.6 mg/dl15 (23)14 (22)
  Phosphate >5.0 mg/dl10 (16)5 (8)
  Phosphate binders started7 (11)4 (6)
  • Adverse events are shown for all randomized patients.